Cyclin D2 gene variance and expression level in pediatric acute lymphoblastic leukemia
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30678 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Reham Abdel Haleem Abo Elwafa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Cyclin D2, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Polymorphism, Single Nucleotide, Genetic Predisposition to Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Cyclin D2 (CCND2) is a crucial player in cell cycle regulation. CCND2 polymorphisms contribute to cancer predisposition.
Objectives
To evaluate the association of CCND2 rs3217927 single nucleotide polymorphisms (SNP) and its expression levels with acute lymphoblastic leukemia (ALL) susceptibility in Egyptian children and its potential prognostic role.
Methods
The 5′ nuclease allelic discrimination assay was used to evaluate the frequency of CCND2 rs3217927 SNP in 80 newly diagnosed children with ALL and 80 age‐ and sex‐matched controls. CCND2 relative expression levels were determined by real‐time quantitative polymerase chain reaction.
Results
The genotype analysis revealed that the GG genotype and G allele were significantly more prevalent among ALL patients than controls ( p ˂ .001). Regression analysis demonstrated that Egyptian children carrying only one G allele had about 31‐fold increased risk to develop ALL compared to A allele carriers. CCND2 was overexpressed in ALL patients compared to controls ( p < .001). The CCND2 overexpression was associated with the GG genotype and G allele ( p < .001). Furthermore, G allele was an independent negative prognostic marker for central nervous system (CNS) involvement (odds ratio [OR] = 4.676; 95% confidence interval [CI]: 1.2–18.6), risk stratification (OR = 38; 95% CI: 7.7–188.2), and chemoresistance (OR = 9.864; 95% CI: 5.6–70.3) in ALL patients.
Conclusions
G allele of CCND2 rs3217927 SNP might be associated with increased risk for ALL in Egyptian children besides being an independent negative prognostic marker for their risk stratification and therapeutic outcome. CCND2 rs3217927 SNP genotyping might be used to demarcate ALL patients with aggressive disease phenotypes who may be candidate for alternative targeted therapeutic strategies
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Department of Pediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Zitieren
APA
Elwafa, R. A. H. A., Bordiny, M. E., Salama, M., Fawzy, A., & Omar, O. M. (2023). Cyclin D2 gene variance and expression level in pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30678
Vancouver
Elwafa RAHA, Bordiny ME, Salama M, Fawzy A, Omar OM. Cyclin D2 gene variance and expression level in pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30678
BibTeX
@article{Elwafa2023,
author = {Elwafa, Reham Abdel Haleem Abo and Bordiny, Magdy El and Salama, Mostafa and Fawzy, Amira and Omar, Omneya Magdy},
title = {Cyclin D2 gene variance and expression level in pediatric acute lymphoblastic leukemia},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30678}
}
EUVIMED